The numbers
The Environmental Protection Agency (EPA) has taken a significant step by placing microplastics and pharmaceuticals on a draft list of contaminants in drinking water for the first time. This move comes as part of the agency’s commitment to address growing public concern regarding the safety of drinking water, with specific attention to the substances Americans consume daily.
According to EPA Administrator Lee Zeldin, “This is a direct response to the concern of millions of Americans, who have long demanded answers about what they and their families are drinking every day.” The draft Contaminant Candidate List will be open for public comment for 60 days, allowing citizens to voice their opinions and concerns about these emerging contaminants.
In conjunction with this announcement, the Department of Health and Human Services has launched a $144 million initiative known as STOMP, aimed at measuring and monitoring microplastics in drinking water. Health Secretary Robert F. Kennedy Jr. stated, “Today we mark a turning point — the EPA and HHS are acting together to confront microplastics as a human health threat.” This initiative will design experiments to better understand the effects of microplastics within the human body.
Microplastics and pharmaceuticals have been added to the draft list alongside other concerning chemicals such as PFAS, which have raised alarms over their potential health impacts. Environmental groups have long petitioned the EPA to include microplastics in the Unregulated Contaminant Monitoring Rule, emphasizing the need for comprehensive monitoring of these pollutants.
The inclusion of microplastics and pharmaceuticals in the draft list marks a notable shift in regulatory focus, especially considering the previous administration’s criticisms for rolling back regulations on toxic chemicals in the environment. Observers note that this could signify a renewed commitment to environmental health and safety, although some remain skeptical. Katherine O’Brien remarked, “I think it’s fair to call this theater,” highlighting concerns about the effectiveness of these measures.
Mary Grant, an advocate for clean water, emphasized the urgency of the situation, stating, “We need to understand the scope of the crisis in our drinking water.” The public’s demand for transparency and action regarding water quality has been a driving force behind these recent developments.
As the public comment period unfolds, stakeholders will be closely monitoring the responses and potential changes to the draft list. Details remain unconfirmed regarding the specific timeline for implementing any new regulations or guidelines based on the feedback received. The ongoing discourse surrounding microplastics and pharmaceuticals in drinking water underscores the critical intersection of public health and environmental policy, with many anticipating further action from the EPA and HHS in the near future.
